Vimarsana
Biggest News Aggregation in the World

Luis Sanay News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Luis Sanay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Luis Sanay Today - Breaking & Trending Today

HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE - Vimarsana News

HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE

PLYMOUTH MEETING, Pa., May 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. , today announced that Harmony's management team will participate in a fireside chat at the upcoming Goldman...

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its ... - Vimarsana News

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its ...

WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year

Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript - Vimarsana News

Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript

HRMY earnings call for the period ending March 31, 2024.

Source: fool.com
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST - Vimarsana News

HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and...

HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME - Vimarsana News

HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to...